DelveInsight’s, “Chronic Myelomonocytic Leukemia Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Chronic Myelomonocytic Leukemia pipeline landscape. It covers the Chronic Myelomonocytic Leukaemia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Myelomonocytic Leukaemia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Chronic Myelomonocytic Leukaemia Treatment Landscape. Click here to read more @ Chronic Myelomonocytic Leukaemia Pipeline Outlook

Key Takeaways from the Chronic Myelomonocytic Leukaemia Pipeline Report

• In July 2025, Novartis Pharmaceuticals announced a study is intended to collect safety data from participants who completed the parent protocols but are still benefiting from study treatment. The study population consists of participants who tolerate study treatment of the parent studies. Collecting safety information from long-term exposure might offer the unique opportunity to detect rare Adverse Events.
• DelveInsight’s Chronic Myelomonocytic Leukaemia pipeline report depicts a robust space with 20+ Chronic Myelomonocytic Leukaemia companies working to develop 25+ pipeline therapies for Chronic Myelomonocytic Leukaemia treatment.
• The leading Chronic Myelomonocytic Leukaemia Companies such as Novartis Pharmaceuticals, Treadwell Therapeutics, Nerviano Medical Sciences, NextCure, Inc., Kahr Medical, Faron Pharmaceuticals Ltd, HUTCHMED, Salarius Pharmaceuticals Inc., Newave Pharmaceutical Inc., Immune-Onc Therapeutics Inc., and others.
• Promising Chronic Myelomonocytic Leukaemia Pipeline Therapies such as lenzilumab, AMG 176, Azacitidine, Pevonedistat, Decitabine, 5-Azacitidine, Tipifarnib, and others.

Stay informed about the cutting-edge advancements in Chronic Myelomonocytic Leukaemia Treatments. Download for updates and be a part of the revolution in oncology care @ Chronic Myelomonocytic Leukaemia Clinical Trials Assessment

Chronic Myelomonocytic Leukaemia Emerging Drugs Profile

• Timdarpacept: ImmuneOnco Biopharma

Timdarpacept is a recombinant Signal Regulatory Protein α (SIRPα) IgG1 fusion protein currently being evaluated as a treatment for CMML. This innovative therapeutic agent functions by blocking the “”Don’t eat me”” signal and activating the “”Eat me”” signal, which enhances Antibody-Dependent Cellular Phagocytosis (ADCP) and promotes the immune system’s ability to target and eliminate tumor cells. Currently, the drug is in Phase III stage of its development for the treatment of Chronic Myelomonocytic Leukemia.

• IO-202: Immune-Onc Therapeutics

IO-202 is a first-in-class, humanized IgG1 monoclonal antibody designed to target the Leukocyte Immunoglobulin-Like Receptor Subfamily B4 (LILRB4), which is overexpressed in chronic myelomonocytic leukemia (CMML) cells. By binding with high affinity to LILRB4, IO-202 facilitates antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), enhancing the immune system’s ability to eliminate malignant cells. The drug has received both fast track and orphan drug designations from the FDA, underscoring its potential as a therapeutic option for patients with CMML. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of Chronic Myelomonocytic Leukemia.

• STX-0712: SOLU THERAPEUTICS, INC.

STX-0712 is an innovative therapeutic agent developed by Solu Therapeutics for the treatment of Chronic Myelomonocytic Leukemia (CMML). This drug is a CCR2-targeting Cytotoxicity Targeting Chimera (CyTAC) designed to selectively bind to CCR2, a receptor that is highly expressed on malignant monocytes in these hematologic cancers. The drug has shown robust activity in CMML, with favorable pharmacokinetics and tolerability observed in non-human primate models. Currently, the drug is in Preclinical stage of its development for the treatment of Chronic Myelomonocytic Leukemia.

The Chronic Myelomonocytic Leukaemia pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Myelomonocytic Leukaemia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Myelomonocytic Leukaemia Treatment.
• Chronic Myelomonocytic Leukaemia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Chronic Myelomonocytic Leukaemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Myelomonocytic Leukaemia market.

Get a detailed analysis of the latest innovations in the Chronic Myelomonocytic Leukaemia pipeline. Explore DelveInsight’s expert-driven report today! @ Chronic Myelomonocytic Leukaemia Unmet Needs

Chronic Myelomonocytic Leukaemia Companies

Novartis Pharmaceuticals, Treadwell Therapeutics, Nerviano Medical Sciences, NextCure, Inc., Kahr Medical, Faron Pharmaceuticals Ltd, HUTCHMED, Salarius Pharmaceuticals Inc., Newave Pharmaceutical Inc., Immune-Onc Therapeutics Inc., and others.

Chronic Myelomonocytic Leukemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Chronic Myelomonocytic Leukaemia Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Discover the latest advancements in Chronic Myelomonocytic Leukaemia Treatment by visiting our website. Stay informed about how we’re transforming the future of oncology @ Chronic Myelomonocytic Leukaemia Market Drivers and Barriers, and Future Perspectives

Scope of the Chronic Myelomonocytic Leukaemia Pipeline Report

• Coverage- Global
• Chronic Myelomonocytic Leukaemia Companies- Novartis Pharmaceuticals, Treadwell Therapeutics, Nerviano Medical Sciences, NextCure, Inc., Kahr Medical, Faron Pharmaceuticals Ltd, HUTCHMED, Salarius Pharmaceuticals Inc., Newave Pharmaceutical Inc., Immune-Onc Therapeutics Inc., and others.
• Chronic Myelomonocytic Leukaemia Pipeline Therapies- lenzilumab, AMG 176, Azacitidine, Pevonedistat, Decitabine, 5-Azacitidine, Tipifarnib, and others.
• Chronic Myelomonocytic Leukaemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Chronic Myelomonocytic Leukaemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Chronic Myelomonocytic Leukaemia Pipeline on our website @ Chronic Myelomonocytic Leukaemia Emerging Drugs and Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Chronic Myelomonocytic Leukemia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Chronic Myelomonocytic Leukemia– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Timdarpacept: ImmuneOnco Biopharma
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Drug Name: Company Name
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. IO-202: Immune-Onc Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. STX-0712: SOLU THERAPEUTICS, INC.
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Chronic Myelomonocytic Leukemia Key Companies
21. Chronic Myelomonocytic Leukemia Key Products
22. Chronic Myelomonocytic Leukemia- Unmet Needs
23. Chronic Myelomonocytic Leukemia- Market Drivers and Barriers
24. Chronic Myelomonocytic Leukemia- Future Perspectives and Conclusion
25. Chronic Myelomonocytic Leukemia Analyst Views
26. Chronic Myelomonocytic Leukemia Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/chronic-myelomonocytic-leukaemia-pipeline-insight